Systemic Lupus Erythematosus Highlights 2017 - Designation, Collaboration, and Developments


Free Press Release DB | Press Release Date : Aug 31, 2017  Download


The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.


Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.




Contact Person & Company

Name

:

Vijay Kumar

Company

:

P&s Market Research

Contact Numbers

Telephone No.

:

1-888-778-7886

Fax No.

:

Handphone No.

:

Website

Website 1

:

Go To PR Site

Website 2

:

Youtube

:

PR Tags

:

Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Pipeline, Systemic Lupus Erythematosus Highlights, Systemic Lupus Erythematosus Pipeline Analysis,

Address

347, 5th Ave. #1402

10016, New York City

United States

United States


Contact The Author



Contact Vijay Kumar






More Press Release From Author



Revenue Cycle Management Market - Size, Analysis and Demand, 2023


Free Press Release DB :

The worldwide revenue cycle management market is witnessing considerable growth due to increasing regulatory requirements for the usage of revenue cycle management. --> Read This Press Release !



By : Vijay, Kumar ( Sep 19, 2017 )
Category : Healthcare Press Release | Country : United States Press Release




Amyotrophic Lateral Sclerosis - Pipeline Analysis, Collaboration, 2017


Free Press Release DB :

According to a new research report, Amyotrophic lateral sclerosis currently exhibits a pipeline with 72 drug candidates. --> Read This Press Release !



By : Vijay, Kumar ( Sep 19, 2017 )
Category : Healthcare Press Release | Country : United States Press Release




Orthopedic Soft Tissue Repair Market - Analysis, Size and Forecast to 2023


Free Press Release DB :

A soft tissue injury is the damage of ligaments, muscles and tendons of hip, knee, shoulder and elbow joint. A soft tissue injury usually occurs from a strain, sprain and continuous use of a particular part of the body and it can result in swelling. --> Read This Press Release !



By : Vijay, Kumar ( Sep 15, 2017 )
Category : Healthcare Press Release | Country : United States Press Release





Read More Articles From Vijay Kumar



Disclaimer

The author of the press releases are solely responsible for the content of their press releases. Freepressreleasedb.com can't be held liable for the content posted by author. Please check the accuracy of the press release before using the press release. If necessary please contact the author. Thank you.




Report Abuse